Kronox Lab Sciences Ltd

Kronox Lab Sciences Limited has received a Draft Letter of Offer (DLOF) for an open offer initiated by Indo Borax and Chemicals Limited, along with Zenrock Chemicals Private Limited (PAC). The offer aims to acquire up to 95,70,000 equity shares, representing 25.79% of the voting share capital, at a price of ₹157.27 per share. This open offer is being made pursuant to SEBI (SAST) Regulations, 2011. The final Letter of Offer is subject to SEBI's approval.

IIFL Capital Services Ltd, acting as the Manager to the Open Offer, has submitted a Draft Letter of Offer to the public shareholders of Kronox Lab Sciences Ltd. The open offer is being made by Indo Borax and Chemicals Limited, along with Zenrock Chemicals Private Limited (PAC), to acquire up to 95,70,000 equity shares, representing 25.79% of the voting share capital. The offer price is ₹157.27 per share, payable in cash. This offer is made pursuant to SEBI (SAST) Regulations, 2011. The final Letter of Offer is subject to SEBI's approval. The offer is not conditional and not a competing offer.

Indo Borax and Chemicals Limited, along with Zenrock Chemicals Private Limited, has published a Detailed Public Statement (DPS) for an open offer to acquire up to 95,70,000 equity shares of Kronox Lab Sciences Limited. This represents 25.79% of the voting share capital. The offer is being managed by IIFL Capital Services Limited and complies with SEBI (SAST) Regulations, 2011. The DPS was published on August 28, 2026, in multiple newspapers. The offer size is slightly below the 26% threshold mandated by Regulation 7(1) due to the available public shareholding.

IIFL Capital Services Ltd, acting as the Manager to the Open Offer, has submitted a Detailed Public Statement to BSE regarding an open offer by Indo Borax and Chemicals Limited, along with Zenrock Chemicals Private Limited (PAC), to the public shareholders of Kronox Lab Sciences Limited. The offer is for the acquisition of up to 95,70,000 equity shares, representing 25.79% of the voting share capital. This open offer is made pursuant to SEBI (SAST) Regulations, 2011. The Detailed Public Statement was published in various newspapers on August 28, 2026, following a Public Announcement on August 20, 2026. The offer size is determined by the available public shareholding, which is slightly below the 26% threshold typically required by Regulation 7(1) of SEBI (SAST) Regulations.

Kronox Lab Sciences Ltd has announced that Wednesday, September 09, 2026, has been fixed as the Record Date for determining shareholder eligibility for the final dividend for the financial year ended March 31, 2026. This follows the Board of Directors' recommendation of a final dividend of ₹0.50 per equity share of ₹10 each. The dividend payment is subject to declaration, and the record date is in compliance with SEBI Listing Regulations.

Kronox Lab Sciences Ltd has announced its 17th Annual General Meeting (AGM) to be held on Wednesday, September 16, 2026, at 11:00 AM via Video Conferencing/Other Audio Visual Means (VC/OAVM). The meeting agenda includes the adoption of audited standalone financial statements for the fiscal year ended March 31, 2026, declaration of a final dividend of ₹0.50 per equity share for FY 2025-26, and the re-appointment of Mr. Jogindersingh Jaswal as a director. Additionally, the AGM will seek ratification of remuneration for the Cost Auditors for FY 2026-27. The notice and annual report for 2025-26 are being sent electronically to shareholders.

Kronox Lab Sciences Ltd has announced its 17th Annual General Meeting (AGM) to be held on Wednesday, September 16, 2026, at 11:00 AM via Video Conferencing/Other Audio Visual Means (VC/OAVM). The agenda includes the adoption of the Audited Standalone Financial Statement for the fiscal year ended March 31, 2026, declaration of a final dividend of ₹0.50 per equity share for FY 2025-26, and the re-appointment of Mr. Jogindersingh Jaswal as a Director. Additionally, the AGM will seek ratification of remuneration for the Cost Auditors, M/s. Diwanji & Associates, for the financial year 2026-27, amounting to ₹90,000 per annum plus applicable taxes. The notice and Annual Report for 2025-26 are being sent electronically to shareholders.

Kronox Lab Sciences Ltd has re-submitted its Annual Report for the fiscal year 2025-26, along with the Notice of its 17th Annual General Meeting (AGM) scheduled for September 16, 2026. The re-submission was necessitated by a clerical error in the event number provided by the AGM service provider. The Annual Report details the company's milestones, clientele, CSR activities, manufacturing facilities, board profile, chairman's message, corporate overview, and financial statements. Key milestones include the commencement of manufacturing at Unit-I in 2009, export of specialty fine chemicals in 2010, and listing on NSE & BSE in 2024.

Kronox Lab Sciences Limited has announced its 17th Annual General Meeting (AGM) scheduled for September 16, 2026, at 11:00 AM. The meeting will be conducted via Video Conferencing/Other Audio Visual Means. The company is submitting its Annual Report for the Financial Year 2025-26, along with the Notice of the AGM, as per SEBI regulations. The report details corporate information, statutory reports, financial statements, and a corporate overview including milestones, clientele, CSR activities, manufacturing facilities, and board profiles. Key milestones include the commencement of manufacturing at Unit-I in 2009, exports of specialty fine chemicals in 2010, expansion for pharma and nutraceuticals in 2011, acquisition of land for Unit-II in 2014, and listing on NSE & BSE in 2024. The company also achieved a turnover of ₹100 crore in FY 2025-26.

Kronox Lab Sciences Limited has received a public announcement regarding an open offer from Indo Borax & Chemicals Limited, along with Zenrock Chemicals Private Limited, to acquire up to 95,70,000 equity shares. This represents 25.79% of the company's voting share capital. The offer is being made in compliance with the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. IIFL Capital Services Limited is acting as the Manager to the Offer. The acquisition aims to increase the Acquirer's stake in Kronox Lab Sciences Limited.